Kiora Pharmaceuticals Inc (KPRX) stock
KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.93−0.05 (-5.30%)
Close on Nov 17, 2026Market cap $4.11MP/E –Yield –
Kiora Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Kiora Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.86M, up 6.8% year over year. For fiscal 2025 it was $10.78M, up 37.5% from the year before. Over ten years it grew 14.8% a year on average. The highest annual figure on record is $10.78M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.78M | +37.5% |
| FY2024 | Dec 31, 2024 | $7.84M | +94.7% |
| FY2023 | Dec 31, 2023 | $4.03M | +16.8% |
| FY2022 | Dec 31, 2022 | $3.45M | -35.5% |
| FY2021 | Dec 31, 2021 | $5.35M | +50.0% |
| FY2020 | Dec 31, 2020 | $3.57M | -33.8% |
| FY2019 | Dec 31, 2019 | $5.39M | -33.1% |
| FY2018 | Dec 31, 2018 | $8.06M | -22.0% |
| FY2017 | Dec 31, 2017 | $10.33M | +22.7% |
| FY2016 | Dec 31, 2016 | $8.42M | +210.0% |
| FY2015 | Dec 31, 2015 | $2.72M | +411.6% |
| FY2014 | Dec 31, 2014 | $531.12K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.08M | -19.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.12M | -16.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.93M | +52.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.73M | +24.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.59M | +26.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.53M | +50.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.92M | +73.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.18M | +101.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.05M | +47.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.68M | +284.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.11M | +32.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.09M | -18.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.39M | +145.4% |
| Q1 FY2023 | Mar 31, 2023 | $438.28K | -38.1% |
| Q4 FY2022 | Dec 31, 2022 | $841.62K | -16.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.33M | -18.2% |
| Q2 FY2022 | Jun 30, 2022 | $567.23K | -60.6% |
| Q1 FY2022 | Mar 31, 2022 | $707.93K | -44.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.00M | -0.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.63M | +65.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.44M | +128.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.28M | +36.5% |
| Q4 FY2020 | Dec 31, 2020 | $1.01M | -32.5% |
| Q3 FY2020 | Sep 30, 2020 | $985.88K | -59.0% |
| Q2 FY2020 | Jun 30, 2020 | $631.11K | -17.4% |
| Q1 FY2020 | Mar 31, 2020 | $938.04K | +30.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.50M | +4.2% |
| Q3 FY2019 | Sep 30, 2019 | $2.41M | +6.5% |
| Q2 FY2019 | Jun 30, 2019 | $763.90K | -58.4% |
| Q1 FY2019 | Mar 31, 2019 | $721.48K | -71.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.44M | -53.3% |
| Q3 FY2018 | Sep 30, 2018 | $2.26M | -28.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.84M | -18.8% |
| Q1 FY2018 | Mar 31, 2018 | $2.52M | +38.9% |
| Q4 FY2017 | Dec 31, 2017 | $3.08M | +19.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.18M | +29.7% |
| Q2 FY2017 | Jun 30, 2017 | $2.26M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.82M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.58M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.45M | – |
See a number that looks wrong?